Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain (Tarot)
This study has been completed.
Sponsor:
Bayer
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT01453400
First received: October 13, 2011
Last updated: May 22, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is to evaluate the onset of relief provided by a single, oral dose of fast release aspirin 1000 mg compared to acetaminophen 1000 mg and placebo in subjects with sore throat pain.
| Condition | Intervention | Phase |
|---|---|---|
|
Pharyngitis |
Drug: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo Drug: Acetaminophen + placebo Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Onset of Action of a Fast Release Aspirin Tablet and Acetaminophen Caplet in Sore Throat Pain |
Resource links provided by NLM:
Further study details as provided by Bayer:
Primary Outcome Measures:
- Time to meaningful pain relief from the Sore Throat Pain Intensity Scale (STPIS) 100 mm visual analog scale [ Time Frame: Up to two hours ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Global assessment of the investigational product as a pain reliever by grading from 0 to 4 (from poor to excellent) [ Time Frame: Two hours postdose or immediately before the intake of rescue medication ] [ Designated as safety issue: No ]
- Time to first perceptible relief (defined as the time when the subject presses the first stopwatch) [ Time Frame: Up to two hours ] [ Designated as safety issue: No ]
- Time weighted sum of pain intensity differences (PID) scores over first hour [ Time Frame: Up to one hour ] [ Designated as safety issue: No ]
- Time weighted sum of pain intensity differences (PID) scores over 2 hours [ Time Frame: Up to two hours ] [ Designated as safety issue: No ]
- Percentage difference from baseline Sore Throat Pain Intensity Scale (STPIS) to STPIS at time of meaningful relief [ Time Frame: Up to two hours ] [ Designated as safety issue: No ]
| Enrollment: | 177 |
| Study Start Date: | September 2011 |
| Study Completion Date: | April 2012 |
| Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Arm 1 |
Drug: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo
Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
|
| Active Comparator: Arm 2 |
Drug: Acetaminophen + placebo
Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
|
| Placebo Comparator: Arm 3 |
Drug: Placebo
Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Healthy, ambulatory, male and female subjects ≥ 18 years of age
- Presence of sore throat due to upper respiratory tract infection (URTI)
- Onset of sore throat pain within six days of the screening period
- Baseline sore throat pain intensity score ≥ 60 mm on the Sore Throat Pain Intensity Scale
- Have a score ≥ 5 on the Tonsillopharyngitis Assessment
- Female subjects of childbearing potential who are currently sexually active must be using a medically acceptable form of birth control for at least one month prior to screening (three months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Nuvaring, Depo-Provera, or double-barrier and have a negative pregnancy test at screening/treatment period. Female subjects of non-childbearing potential must be amenorrheic for at least two years or had a hysterectomy and/or bilateral oophorectomy.
- Understand the pain rating assessments
Exclusion Criteria:
- History of hypersensitivity to aspirin, salicylates, other nonsteroidal anti-inflammatory drugs, acetaminophen, opioid analgesics, and similar drugs
- Use of any "cold medication" (i.e. decongestants, antihistamines, expectorants, antitussives) within four hours preceding administration of the investigational product
- Use of any immediate release analgesic/antipyretic within four hours or use of any sustained release or long-acting analgesic/antipyretic within twelve hours preceding administration of the investigational product
- Consumption of alcoholic beverages, or foods and beverages containing xanthines within two hours prior to administration of the investigational product
- Use of any sore throat lozenges, sprays, cough drops, menthol-containing products within one hour preceding administration of the investigational product
- Presence of cough that causes throat discomfort
- Presence of mouth-breathing or any respiratory condition that, in the Investigator's judgment, could compromise breathing
- Evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies for which aspirin or acetaminophen is contraindicated
- Relevant concomitant disease such as medically uncontrolled asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than fifty percent obstruction
- History of gastrointestinal bleeding or perforation related to previous non-steroidal anti-inflammatory therapy.
- Current or past history of a bleeding disorder
- Self reported alcoholism or drug abuse within two years prior to screening or routine consumption of three or more alcohol containing beverages per day
- Habituation to analgesic drugs or tranquilizers (i.e., routine use of five or more times per week for greater than three weeks)
- Acute illness, local infection, or disease (other than URTI with pharyngeal infection) that can interfere with the conduct of the study
- Current use of blood thinning (anticoagulant), low dose aspirin, or steroid drug
- Has initiated treatment for depression within the past thirty days
- Females who are pregnant or lactating
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Head Clinical and Medical Affairs, Bayer Consumer Care L.L.C. |
| ClinicalTrials.gov Identifier: | NCT01453400 History of Changes |
| Other Study ID Numbers: | 15772 |
| Study First Received: | October 13, 2011 |
| Last Updated: | May 22, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Bayer:
|
aspirin acetylsalicylic acid pharyngitis sore throat |
Additional relevant MeSH terms:
|
Pharyngitis Pharyngeal Diseases Stomatognathic Diseases Respiratory Tract Infections Respiratory Tract Diseases Otorhinolaryngologic Diseases Acetaminophen Aspirin Antipyretics Physiological Effects of Drugs Pharmacologic Actions Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors |
ClinicalTrials.gov processed this record on June 13, 2013